Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective

Authors Renzo Galanello

Published 15 November 2007 Volume 2007:3(5) Pages 795—805

Renzo Galanello

Ospedale Regionale Microcitemie, ASL 8 – Dipartimento di Scienze Biomediche e Biotecnologie, Università degli Studi di Cagliari, Italy

Abstract: Deferiprone is an orally active iron chelator which has emerged from an extensive search for new treatment of iron overload. Comparative studies have shown that at comparable doses deferiprone may be as effective as deferoxamine in removing body iron. Retrospective and prospective studies have shown that deferiprone monotherapy is significantly more effective than deferoxamine in improving myocardial siderosis in thalassemia major. Agranulocytosis is the most serious side effect associated with the use of deferiprone, occurring in about 1% of the patients. More common but less serious side effects are gastrointestinal symptoms, arthralgia, zinc deficiency, and fluctuating transaminases levels. Deferiprone can be used in combination with desferrioxamine. This regimen of chelation is tolerable and attractive for patients unable to comply with standard deferoxamine infusions or with inadequate response to deferiprone alone. Combination therapy has been effectively used in the management of severe cardiac siderosis.

Keywords: deferiprone, iron overload, thalassemia, deferoxamine

Download Article [PDF] 

Readers of this article also read:

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Clinical utility of eslicarbazepine: current evidence

Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A

Drug Design, Development and Therapy 2015, 9:781-789

Published Date: 10 February 2015

Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound

Yang FY, Teng MC, Lu M, Liang HF, Lee YR, Yen CC, Liang ML, Wong TT

International Journal of Nanomedicine 2012, 7:965-974

Published Date: 21 February 2012

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno

Therapeutics and Clinical Risk Management 2008, 4:1305-1313

Published Date: 5 December 2008

Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics

Trung D Tran, Shelton D Caruthers, Michael Hughes, John N Marsh, Tillmann Cyrus, et al

International Journal of Nanomedicine 2007, 2:515-526

Published Date: 15 January 2008

Prevention of shingles: safety and efficacy of live zoster vaccine

Dianna Quan, Randall J Cohrs, Ravi Mahalingam, Donald H Gilden

Therapeutics and Clinical Risk Management 2007, 3:633-639

Published Date: 15 September 2007

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia

Alberto Grossi, Francesca Balestri, Simone Santini

Therapeutics and Clinical Risk Management 2007, 3:269-275

Published Date: 15 May 2007

Management of age-related osteoporosis and prevention of associated fractures

Eric J MacLaughlin, Rebecca B Sleeper, Danny McNatty, Cynthia L Raehl

Therapeutics and Clinical Risk Management 2006, 2:281-295

Published Date: 15 September 2006